ROS1 Biomarkers News and reporting on ROS1 biomarkers. Jun 3, 2022 BMS to Acquire Turning Point Therapeutics in Deal Valued at $4.1B Apr 13, 2022 Turning Point Therapeutics' NDA Submission for Repotrectinib in Sight Based on Registrational Data Jan 7, 2022 Nuvalent Begins Study of ROS1 Inhibitor in Advanced NSCLC, Solid Tumors Dec 14, 2021 AnHeart Raises $61M in Oversubscribed Series B Financing Round Oct 26, 2021 AnHeart Therapeutics Begins Phase II Taletrectinib Study in ROS1 Fusion-Positive Lung Cancer Jun 18, 2021 AnHeart Therapeutics Begins Phase II Basket Trial of Taletrectinib in NTRK-Positive Solid Tumors May 28, 2021 Zai Lab Begins Phase II Study of Repotrectinib in NSCLC, Solid Tumors in China May 14, 2021 LUNGevity Aims for Widespread Comprehensive Biomarker Test Access With New Patient-Facing Campaign Premium May 11, 2021 Nuvalent Raises $135M in Series B Funding Jan 29, 2021 Turning Point Therapeutics to Discuss Repotrectinib NSCLC Data With FDA Jan 27, 2021 Nuvalent Launches With $50 Million in Series A Funding Dec 14, 2020 Daiichi Sankyo, AstraZeneca Begin Phase II Datopotamab Deruxtecan Trial in NSCLC Nov 10, 2020 HitGen Outlicenses TRK/ROS1 Inhibitor to Baiyunshan for Development in Mainland China Sep 14, 2020 COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials Aug 19, 2020 Turning Point's Repotrectinib Yields Promising Early Data in ROS1-, NTRK-Positive Cancers Aug 3, 2020 Roche's Rozlytrek Garners Conditional Authorization in Europe for Cancers With NTRK, ROS1 Fusions Jul 21, 2020 AnHeart Doses First ROS1 Fusion-Positive NSCLC Patient in Phase II Trial of Taletrectinib Jul 7, 2020 Precision Oncology Trials Still Enroll Mostly White Patients Despite Initiatives, Calls to Diversify Jul 7, 2020 Turning Point Therapeutics, Zai Lab Enter License Agreement for Repotrectinib in Greater China Jun 15, 2020 UK's NICE Backs Roche's Rozlytrek for Patients With Advanced, ROS1-Positive Lung Cancer Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
